Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Ultragenyx Second Quarter 2025 Financial Results Conference Call.
Ultragenyx Pharmaceutical Inc. (RARE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Motley Fool Asset Management Bryan Hinmon | 167,448 | $6,088,409 | +99% | 0.28% |
| 2. | BIT Capital GmbH Jan Beckers | 2,055 | $74,720 | -91% | 0% |
| 3. | Antipodes Partners Jacob Mitchell | 0 | $0 | 0% | |
| 4. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% | |
| 5. | Cutter Capital Vince Aita | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.63 | 5,000 | $218,150.00 | 472,479 | 2019-09-11 | Filing | |
| $52.96 | 1,647 | $87,225.12 | 2,559,741 | 2017-08-28 | Filing | |
| $52.40 | 5,853 | $306,697.20 | 2,558,094 | 2017-08-28 | Filing | |
| $21.00 | 175,000 | $3,675,000.00 | 3,260,240 | 2014-01-31 | Filing | |
| $21.00 | 4,500 | $94,500.00 | 84,255 | 2014-01-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $37.39 | 2,405 | $89,922.95 | 15,344 | 2025-06-20 | Filing | |
| $39.24 | 520 | $20,404.80 | 71,530 | 2025-05-05 | Filing | |
| $35.11 | 242 | $8,496.62 | 71,680 | 2025-04-21 | Filing | |
| $40.40 | 1,785 | $72,114.00 | 106,169 | 2025-03-06 | Filing | |
| $42.10 | 6,028 | $253,778.80 | 265,238 | 2025-03-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,712,931 | $62,291,362 | 0% | |
| 2. | 1,163,755 | $42,314,132 | 0.06% | |
| 3. | 526,267 | $19,135,883 | 0.11% | |
| 4. | 501,056 | $18,218,396 | 0.03% | |
| 5. | 486,632 | $17,693,940 | 0.01% |
News See All
Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory
We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on Valueinvesting subreddit by bluespacecolombo. In this article, we will summarize the bulls’ thesis on RARE.
Ultragenyx Pharmaceutical Inc. (RARE) Gets FDA CRL for UX111, Vows Quick Resubmission
Ultragenyx Pharmaceutical Inc.
11 Best Future Stocks to Buy Now
Over the past year, investors have poured money into cutting-edge technologies like artificial intelligence and electric cars.
Ultragenyx Pharmaceutical (RARE) Gets a Complete Response Letter for UX111
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the 11 Best All-Time Low Stocks to Buy According to Analysts. On July 12, Ultragenyx Pharmaceutical Inc.
11 Best All-Time Low Stocks to Buy According to Analysts
On July 19, Jordan Jackson, global market strategist at JPMorgan Asset Management, joined CNBC Television to talk about what’s next for the market as companies are reporting their Q2 2025 quarterly ...
Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the Best 52-Week Low Stocks to Buy According to Analysts.
12 Best 52-Week Low Stocks to Buy According to Analysts
On July 15, the Consumer Price Index data revealed that core inflation increased by 0.2% on the month; however, the annual rate of 2.9% remains within the estimated range.
12 Oversold NASDAQ Stocks to Buy Now
On July 14, Max Kettner, chief multi-asset strategist at HSBC, appeared on CNBC to talk about the global markets amid trade tensions.
Ultragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green Light
Ultragenyx fell by 26.05 percent week-on-week as investor sentiment was largely dragged down by the Food and Drug Administration’s (FDA) rejection of its biologics license application (BLA) for its ...
Billionaire Hedge Funds
